 |
 |
The Magneceutical™ Therapy Company, announced today that a pilot study of its proprietary magnetic (Magneceutical™) therapy for Parkinson’s disease patients “demonstrated significant improvement over placebo after 8 weeks (endpoint) of therapy…improvement…persisted up to 2 months (week 16) post-treatment…(and) no treatment-related adverse events were reported.” The pilot study—double-blinded, randomized, placebo-controlled—was designed by consulting neurologist Rajeev Kumar, M.D., a movement disorder specialist and medical director of the Colorado Neurological Institute Movement Disorder Center, Englewood, Colo. There were two groups of six PD patients each, with one group serving as the control group and the other as the treatment group. The study data was presented by Olga Klepitskaya, M.D., a neurologist at the University of Colorado Health Sciences Center, and Dr. Kumar at the “22nd Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson’s Disease and Other Movement Disorders.” “Especially in Parkinson’s disease, there is a tremendous placebo effect, which makes it difficult to discern whether or not what you’re observing is a placebo effect in response to expectations of improvement, or truly improvement. That is the challenge, and that is why the data from this study is highly positive,” said Dr. Kumar. “It suggests that there may truly be something here beyond the placebo effect, and that’s very important and warrants further investigation. “Because we don’t know the mechanism of action of magnetic therapy, it makes it very difficult to know what we’re going to see in a larger study in terms of what the limits of the therapy might be,” added Dr. Kumar. “What’s realistic is some improvement perhaps in motor and non-motor symptoms which are refractory to conventional therapy. That would be great. And that’s a reasonable expectation of this therapy. Indeed, larger placebo-controlled studies should be undertaken to confirm and further investigate the benefits of this unique, noninvasive and potentially promising treatment for Parkinson’s disease.” “There is no cure for Parkinson’s disease,” said Allen Braswell, president and CEO of Pico-Tesla. “However, early clinical data such as those produced by this pilot study strongly suggest that our Magneceutical™ Therapy may improve both motor and non-motor symptoms of PD. Therefore we are extremely excited to continue with the clinical development of Magneceutical™ Therapy.” Magneceutical™ Therapy involves the use of an extremely low-level electromagnetic field (EMF) applied by a specially designed device—the Resonator™, invented by Dr. Jerry I. Jacobson, along with proprietary therapeutic protocols—intended to improve a number of the signs and symptoms of Parkinson’s and other neurological-based diseases. Parkinson’s disease (also known as ‘PD’) affects 1.5 million people in the U.S., with 60,000 news cases diagnosed each year. PD is a chronic and progressive degenerative disease of the brain that is characterized by muscle rigidity, resting tremors and, in extreme cases, nearly complete loss of movement. The popular actor Michael J. Fox, who has PD, has raised awareness of the disease through the Michael J. Fox Foundation for Parkinson's Research (MJFF). About Pico-Tesla Magnetic Therapies, Inc. Privately held Pico-Tesla Magnetic Therapies is an emerging medical technology company based in Littleton, Colo. Three pilot studies suggest its Magneceutical™ Therapy—made possible by its proprietary Resonator™ device along with proprietary treatment protocols—may give neurologists a whole new way of treating Parkinson’s disease and other neurological-based disorders and diseases. CAUTION: The Resonator™ device is an Investigational Device limited by federal (or United States) law to investigational use. The Resonator™ device is not for sale, nor is the Magneceutical™ Therapy generally available outside of Investigational Review Board (IRB)- approved clinical studies. Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi- bin/mmg.cgi?eid=6053155&lang=en Contacts ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn